JPWO2022260132A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022260132A5 JPWO2022260132A5 JP2023527921A JP2023527921A JPWO2022260132A5 JP WO2022260132 A5 JPWO2022260132 A5 JP WO2022260132A5 JP 2023527921 A JP2023527921 A JP 2023527921A JP 2023527921 A JP2023527921 A JP 2023527921A JP WO2022260132 A5 JPWO2022260132 A5 JP WO2022260132A5
- Authority
- JP
- Japan
- Prior art keywords
- surface area
- body surface
- agent according
- therapy
- fluorouracil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 22
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 13
- 229960002949 fluorouracil Drugs 0.000 claims 13
- 238000002560 therapeutic procedure Methods 0.000 claims 12
- 238000001990 intravenous administration Methods 0.000 claims 8
- 230000037396 body weight Effects 0.000 claims 7
- 229960000397 bevacizumab Drugs 0.000 claims 6
- 229960005395 cetuximab Drugs 0.000 claims 6
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 claims 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 5
- 229960001756 oxaliplatin Drugs 0.000 claims 5
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000002648 combination therapy Methods 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000011301 standard therapy Methods 0.000 claims 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical group [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229940121581 magrolimab Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000011221 initial treatment Methods 0.000 claims 2
- 229960000779 irinotecan hydrochloride Drugs 0.000 claims 2
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 229940121530 balstilimab Drugs 0.000 claims 1
- 229940121418 budigalimab Drugs 0.000 claims 1
- 229940067219 cetrelimab Drugs 0.000 claims 1
- 229940121432 dostarlimab Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940066764 geptanolimab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 229940121482 prolgolimab Drugs 0.000 claims 1
- 229940018007 retifanlimab Drugs 0.000 claims 1
- 229940018566 serplulimab Drugs 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950007123 tislelizumab Drugs 0.000 claims 1
- 229940121514 toripalimab Drugs 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 229940052007 zimberelimab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024157591A JP2024174997A (ja) | 2021-06-10 | 2024-09-11 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021097024 | 2021-06-10 | ||
| JP2021097027 | 2021-06-10 | ||
| JP2021097024 | 2021-06-10 | ||
| JP2021097027 | 2021-06-10 | ||
| PCT/JP2022/023300 WO2022260132A1 (ja) | 2021-06-10 | 2022-06-09 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024157591A Division JP2024174997A (ja) | 2021-06-10 | 2024-09-11 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022260132A1 JPWO2022260132A1 (https=) | 2022-12-15 |
| JPWO2022260132A5 true JPWO2022260132A5 (https=) | 2023-09-29 |
| JP7556468B2 JP7556468B2 (ja) | 2024-09-26 |
Family
ID=84424587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527921A Active JP7556468B2 (ja) | 2021-06-10 | 2022-06-09 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
| JP2024157591A Pending JP2024174997A (ja) | 2021-06-10 | 2024-09-11 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024157591A Pending JP2024174997A (ja) | 2021-06-10 | 2024-09-11 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240254226A1 (https=) |
| EP (1) | EP4353265A4 (https=) |
| JP (2) | JP7556468B2 (https=) |
| KR (1) | KR20240019111A (https=) |
| AU (1) | AU2022289317A1 (https=) |
| CA (1) | CA3222362A1 (https=) |
| TW (1) | TW202317183A (https=) |
| WO (1) | WO2022260132A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| JP7308191B2 (ja) * | 2017-10-18 | 2023-07-13 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７剤ベースの卵巣癌療法 |
| US12053523B2 (en) * | 2017-12-13 | 2024-08-06 | North Carolina State University | Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use |
| JP7491220B2 (ja) | 2018-11-27 | 2024-05-28 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 |
| EP3965816A1 (en) * | 2019-05-06 | 2022-03-16 | MedImmune Limited | Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer |
| JP2022552748A (ja) * | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
-
2022
- 2022-06-09 EP EP22820311.3A patent/EP4353265A4/en active Pending
- 2022-06-09 WO PCT/JP2022/023300 patent/WO2022260132A1/ja not_active Ceased
- 2022-06-09 US US18/566,424 patent/US20240254226A1/en active Pending
- 2022-06-09 KR KR1020237041872A patent/KR20240019111A/ko active Pending
- 2022-06-09 CA CA3222362A patent/CA3222362A1/en active Pending
- 2022-06-09 AU AU2022289317A patent/AU2022289317A1/en active Pending
- 2022-06-09 JP JP2023527921A patent/JP7556468B2/ja active Active
- 2022-06-09 TW TW111121390A patent/TW202317183A/zh unknown
-
2024
- 2024-09-11 JP JP2024157591A patent/JP2024174997A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024526145A5 (https=) | ||
| JP2025020147A5 (https=) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JPWO2020111018A5 (https=) | ||
| WO2018068691A1 (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| JP2024527109A5 (https=) | ||
| CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 | |
| JPWO2022260132A5 (https=) | ||
| Chen et al. | Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non–small-cell lung cancer | |
| JP2024514087A5 (https=) | ||
| JP2023531090A5 (https=) | ||
| Fearon et al. | An energy and protein dense, high n-3 fatty acid oral supplement promotes weight gain in cancer cachexia | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| Mizushima et al. | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer | |
| JP2024516970A5 (https=) | ||
| CN110402151A (zh) | 三氟尿苷/盐酸替吡嘧啶、抗肿瘤铂配合物和免疫关卡调节剂之间的组合 | |
| Ducreux et al. | PRODIGE 29-UCGI 26 (NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC) | |
| Kalykaki et al. | A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors | |
| RU2778887C2 (ru) | Комбинация трифлуридина/типирацил гидрохлорида, противоопухолевого платинового комплекса и модулятора контрольных точек иммунного ответа | |
| Sudha | San Antonio Breast Cancer Symposium 2021-44th Annual Meeting. Virtual/San Antonio-December 7-10, 2021 | |
| Rosen et al. | 400 POSTER Early evidence of tolerability and clinical activity from a phase 1 study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer | |
| CN117460534A (zh) | 基于cd47抑制物质、免疫检查点抑制物质和标准疗法的联用的癌症治疗方法 | |
| Casamartina et al. | EVEROLIMUS THERAPEUTIC DRUG MONITORING IN A CANCER RENAL CANCER PATIENT WHEN DOUBLE DRUG-DRUG INTERACTION IS DETECTED AND A REVIEW OF THE LITERATURE | |
| Gore et al. | Chemotherapy and Colorectal Cancer |